Presentation material can be acquired from Project Mananger by e-mailing email@example.com.
September 30, 10.50 am
NeuroSearch A/S is a leading CNS focused and Scandinavian based biopharmaceutical company listed on NASDAQ OMX Copenhagen (NEUR). The company's core business is development of novel drugs to treat diseases of the central nervous system, and the pipeline comprises eight products in clinical development (Phase I-III). These include Huntexil® (pridopidine), a unique orphan drug in Phase III development for the treatment of Huntington’s disease, and tesofensine ready for Phase III development as a novel drug to treat obesity.
NeuroSearch is well-founded on a drug discovery platform in the field of ion channels and monoamine transporters, ensuring the continuous production of novel preclinical development candidates. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. Further, NeuroSearch has equity interests in a number of private companies in the Life Science industry.
For further information, please visit www.neurosearch.com.
Umecrine Mood, active in the fields of CNS/Psychiatry and Women’s Health, develops first-in-class compounds for the treatment of premenstrual dysphoric disorder (PMDD) and severe premenstrual syndrome PMS.
One mechanism instrumental in the progression of depression in women, is the impairing of the GABA system leading to illness related to the menstrual cycle. PMDD is such a condition, that is prevalent in 3-8% of women in fertile age. PMDD results in large impairment of the affected woman’s quality of life and her surrounding. PMDD is also a great cost for the society in that the women are unable to work during the week prior to menstruation. Umecrine Mood's lead compound, UC1010 is a non-hormonal, selective GABA-A receptor modulator, designed to relieve CNS symptoms such as premenstrual depression and anxiety. UC1010 has proven ability to inhibit the provoking GABA-steroid action as demonstrated in receptor pharmacological studies, in preclinical models of PMDD, and recently also in a clinical pharmacodynamic model in healthy women using a biomarker for PMDD. Due to its high selectivity and specificity, the compound has an excellent safety profile. The company’s offer includes a new unique treatment approach – first-in-class for PMDD and severe PMS, an indication for which there is significant unmet medical need. The company strategy is to take the development as far as to the demonstration of proof-of-concept for the treatment of PMDD, and with this as a basis seek a strategic partnership or a M&A transaction, with a company searching for a new opportunity within the field of Women’s Health or CNS.
For further information, please visit www.umecrine.se/mood.
Diamyd Medical is a Swedish public company focusing on the development of pharmaceuticals in the area of autoimmune diabetes and chronic pain. The Company has clinical-phase products from two proprietary technological platforms in its pipeline; the GAD65 antigen-based therapy Diamyd® for the treatment and prevention of type 1 diabetes, and NP2 for treatment of chronic pain. The diabetes therapy Diamyd® is currently being evaluated in two parallel Phase III studies in Europe and USA. Results are expected in the spring of 2011. In 2010 the company signed an agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, to develop and commercialize the Diamyd® diabetes therapy. The pain therapy NP2 is designed to deliver the natural opioid Enkephalin directly to the nervous system in cancer patients with severe chronic pain using the Company’s proprietary NTDDS technology. NP2 is being evaluated in a Phase I study validating the safety of the entire platform. Diamyd is headquartered in Stockholm, Sweden, with a subsidiary in Pittsburgh, USA. Diamyd is listed on the Nasdaq OMX Nordic Market Small Cap list (ticker: DIAM B), as well as the OTCQX in the US (ticker: DMYDY).
For further information, please visit www.diamyd.com.
September 30, 3.00 pm
Aprea is a drug development company in the oncology field. Its primary drug candidate (APR-246) is a small molecule anticancer drug which belongs to a new chemical class and is protected by a thorough patent portfolio. It originates from research at the world-class medical institute, Karolinska Institutet (KI) in Sweden. APR-246 has been shown to induce apoptosis (programmed cell death) through the tumor suppressor protein p53 – “the guardian of the genome” and has potential applications in a broad spectrum of cancer indications.
For further information, please visit www.aprea.com.
Bactiguard provides world-leading solutions preventing hospital-acquired infections – the 4th largest cause of death in the western world. The use of Bactiguard technology can reduce healthcare cost, lower the use of antibiotics and save lives. The Bactiguard technology consists of an extremely thin noble metal coating, with antimicrobial and biocompatible properties that can be used on all sorts of medical devices. Bactiguard coated urinary catheters have been used in more than 100 million patients in the US. Today Bactiguard offers a full range portfolio within infection prevention in the urinary tract and the portfolio currently expands with products for respiratory and vascular access.
For further information, please visit www.bactiguard.com.
Orexo is a pharmaceutical company focusing on developing treatments for pain and inflammation. Orexo is developing proprietary products based on its proven reformulation technologies, targeted at the Specialty Pharmaceutical market. Orexo intends to commercialise some of these products itself in one or more major markets. Its development activity builds on Orexo’s core competences in R&D, which have previously resulted in several successful products, currently out-licensed through worldwide partnership agreements to larger pharmaceutical companies. Today, Orexo has four products on the market of which AbstralTM is a leading product for the treatment of breakthrough pain in cancer patients in most of Europe. Orexo also has three significant partnerships with major pharmaceutical companies for research and development programs: discovery stage collaborations with Ortho-McNeil Janssen and Janssen Pharmaceutica in respiratory inflammation and with Boehringer Ingelheim for pain, both within the arachidonic acid cascade and a clinical stage development agreement with Novartis in gastrointestinal disorders. Orexo’s head office is located in Uppsala, Sweden.
For further information, please visit www.orexo.com.
October 1, 10.00 am
Athera Biotechnologies AB has a unique and in-depth understanding of the immunological components in atherosclerosis, the inflammatory process leading to cardiovascular disease (CVD). The company currently has two biopharmaceutical product candidates aimed at treating patients with acute heart conditions and a biomarker linked to the therapeutic approach. Low levels of antibodies against phosphorylcholine (anti-PC) are known to be involved in atherosclerosis development and increased risk for acute cardiovascular events, like stroke and myocardial infarction. Athera is investigating the possibilities to develop new immunological therapies to prevent secondary cardiovascular events and to identify the patients who benefit most from this treatment with its companion diagnostics CVDefine®. CVDefine® is a diagnostic kit measuring antibodies against phosphorylcholine (anti-PC).
Athera is part of the Karolinska Development AB (publ) portfolio. Karolinska Development manages one of the largest portfolios of life science companies in Europe. Since 2003, Karolinska Development has built a portfolio of some 40 companies; among the company's projects 12 compounds are undergoing clinical trials and it is estimated that a total of more than 20 substances have first-in-class potential.
For further information, please visit www.athera.se.
Pergamum AB is a biopharmaceutical company with a core competence in multifunctional antimicrobial peptides in dermatology and wound healing. Within Pergamum, biotech start-ups excel as fully integrated Operating Units. A core team of experienced professionals drives drug and business development, while the project management is de-centralized in the Operating Units. Pergamum provides appropriate risk management to enable a higher success rate in drug development and minimize time-to-market. This model provides Pergamum with an attractive diversified product pipeline. Three programs are currently in clinical Phase II.
For further information, please visit www.pergamum.com.
Swedish Orphan Biovitrum AB is a Swedish based niche specialty pharmaceutical company with an international market presence. The company is focused on providing and developing specialist pharmaceuticals for rare disease patients with high medical needs. The portfolio consists of about 60 marketed products and an emerging late stage clinical development pipe-line. Our focus areas are: hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. Swedish Orphan Biovitrum had pro-forma revenues 2009e of about 2 BSEK and approximately 500 employees. The head office is located in Sweden and the share is listed on NASDAQ OMX Stockholm.
For further information, please visit www.sobi.com.